Copyright
©The Author(s) 2018.
World J Gastroenterol. Jan 7, 2018; 24(1): 139-149
Published online Jan 7, 2018. doi: 10.3748/wjg.v24.i1.139
Published online Jan 7, 2018. doi: 10.3748/wjg.v24.i1.139
Ref. | Nation | Age and sex | Probiotic strain and dose | Diagnosis | Control of eradication | Eradication rate % (n/N) |
Boonyaritichaikij et al[27], 2009 | Japan | 62 ± 14 yr | Cheese with L. gasseri OLL2716 5 × 108 CFU/g for 12 mo | SAT | SAT after 12 mo | Probiotic: 29.3% (24/82) |
Male sex: 54.5% | Placebo: 0% (0/6) | |||||
Dore et al[28], 2014 | Italy | Mean age: 51 yr (range, 21-68) | L. reuteri 108 CFU/tablet bid + Pantoprazole 20 mg bid for 60 d | UBT | UBT after 30-40 d | 14.3% (3/21) |
Male sex: 13.6% | ||||||
Francavilla et al[29], 2008 | Italy | 53.3 ± 13.3 yr (probiotics) | L. reuteri ATCC55730 108 CFU/tablet bid for 28 d | UBT (cut-off 3.5%), SAT, RUT, histology | UBT after 4 wk | Probiotic: 0% (0/20) |
52.4 ± 13.1 yr (placebo) | Placebo: 0% (0/20) | |||||
Male sex: 57.5% | ||||||
Gotteland et al[30], 2005 | Chile | 8.5 ± 1.7 | L. acidophilus LB 109/tablet bid or S. boulardii 250 mg + inulin 5 g bid for 8 wk | UBT (cut-off 5‰) | UBT after 1 d | 9.3% (9/97) |
Male sex: 49.6% | L. acidophilus 6.5% (3/46) | |||||
S. boulardii 11.8% (6/51) | ||||||
Myllyluoma et al[31], 2007 | Finland | Mean age: 51 yr (range, 40-69) | Multi-strain (L. rhamnosus GG, L. rhamnosus LC705, P. freudenreichii JS, B. lactis Bb12) 2.5 × 109 CFU/day for 8 wk | UBT (cut-off 2.2%), RUT, histology | UBT after 8 wk | 0% (0/6) |
Pantoflickova et al[32], 2003 | Switzerland | 25 ± 5 yr | L. johnsonii bid for 3 wk, then once daily for 13 wk | UBT (cutoff 5%), histology, culture, RUT, serology | UBT, culture at the end of treatment | Probiotic: 0% (0/25) |
Male sex: 50% | Placebo: 0% (0/25) | |||||
Rosania et al[33], 2012 | Italy | 52.4 ± 21.7 yr (probiotics) | Multi-strain (S. termophilus, L. acidophilus, B. longum, L. plantarum, B. brevis, L. paracasei, B. infantis, L. delbrueckii) 1800 × 109/d for 10 d | UBT (cut-off 4%) | UBT after 4 wk | Probiotic: 32.5% (13/40) |
48.7 ± 25.3 yr (placebo) | Placebo: 0% (0/40) | |||||
Male sex: 42.5% | ||||||
Sakamoto et al[34], 2001 | Japan | 50.1 ± 7.4 yr | Yoghurt + L. gasseri OLL2716 1-1.4 × 107 CFU/g bid for 8 wk | UBT (cut-off 5%) | UBT after 9 wk | 0% (0/29) |
Male sex: 93.1% | ||||||
Shimizu et al[35], 2002 | Japan | Mean age: 12.1 yr (range, 7.4-15.8) Male sex: 41.7% | Yoghurt + L. gasseri OLL2716 1-1.4 × 107 CFU/g bid for 8 wk | SAT, UBT | SAT, UBT after 4 and 10 wk | 0% (0/12) |
Wang et al[36], 2004 | China | Not available | Multi-strain yoghurt (L. acidophilus La5, B. lactis Bb12, L. bulgaricus, S. termophilus) > 107 bacteria/mL for 6 wk | UBT (cut-off 3.5%), histology | UBT after 8 wk | Probiotic: 1.7% (1/59) |
Placebo: 0% (0/11) | ||||||
Namkin et al[37], 2016 | Iran | Age range of 9-12 yr | S. boulardii 250 mg/d for 1 mo | SAT | SAT after 8 wk | Probiotic: 0% (0/12) |
Male sex: 20.8% | Placebo: 0% (0/12) |
- Citation: Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol 2018; 24(1): 139-149
- URL: https://www.wjgnet.com/1007-9327/full/v24/i1/139.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i1.139